The USPTO Patent Trial and Appeal Board (PTAB) issued it first institution decisions on IPR petitions filed by Kyle Bass and his Coalition for Affordable Drugs, denying institution of his challenges to two Orange-book listed patents for Ampyra. Many were watching to see if the PTAB would render a decision based on the “improper purpose” of the challenges, but the PTAB decisions are based on more substantive grounds. For a first look at the PTAB decisions, see this article on Foley’s PharamPatentsblog.